Literature DB >> 22155823

Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

Christal D Sohl1, Kamlendra Singh, Rajesh Kasiviswanathan, William C Copeland, Hiroaki Mitsuya, Stefan G Sarafianos, Karen S Anderson.   

Abstract

The potent antiretroviral 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a promising experimental agent for treating HIV infection. Pre-steady-state kinetics were used to characterize the interaction of EFdA-triphosphate (EFdA-TP) with human mitochondrial DNA polymerase γ (Pol γ) to assess the potential for toxicity. Pol γ incorporated EFdA-TP 4,300-fold less efficiently than dATP, with an excision rate similar to ddATP. This strongly indicates EFdA is a poor Pol γ substrate, suggesting minimal Pol γ-mediated toxicity, although this should be examined under clinical settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155823      PMCID: PMC3294915          DOI: 10.1128/AAC.05729-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy.

Authors:  T N Kakuda; R C Brundage; P L Anderson; C V Fletcher
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

2.  2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.

Authors:  Hiroshi Ohrui; Satoru Kohgo; Hiroyuki Hayakawa; Eiichi Kodama; Masao Matsuoka; Tomohiro Nakata; Hiroaki Mitsuya
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2007       Impact factor: 1.381

3.  Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase.

Authors:  J Y Feng; K S Anderson
Journal:  Biochemistry       Date:  1999-01-05       Impact factor: 3.162

4.  The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Authors:  K A Kirby; K Singh; E Michailidis; B Marchand; E N Kodama; N Ashida; H Mitsuya; M A Parniak; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2011-02-12       Impact factor: 1.770

5.  Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

Authors:  A A Johnson; A S Ray; J Hanes; Z Suo; J M Colacino; K S Anderson; K A Johnson
Journal:  J Biol Chem       Date:  2001-08-28       Impact factor: 5.157

6.  Interaction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma.

Authors:  Adrian S Ray; Joy Y Feng; Eisuke Murakami; Chung K Chu; Raymond F Schinazi; Karen S Anderson
Journal:  Antivir Chem Chemother       Date:  2007

7.  Functional human mitochondrial DNA polymerase gamma forms a heterotrimer.

Authors:  Elena Yakubovskaya; Zhixin Chen; José A Carrodeguas; Caroline Kisker; Daniel F Bogenhagen
Journal:  J Biol Chem       Date:  2005-11-01       Impact factor: 5.157

Review 8.  Viral error catastrophe by mutagenic nucleosides.

Authors:  Jon P Anderson; Richard Daifuku; Lawrence A Loeb
Journal:  Annu Rev Microbiol       Date:  2004       Impact factor: 15.500

9.  Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations.

Authors:  Young-Sam Lee; W Dexter Kennedy; Y Whitney Yin
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

10.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more
  18 in total

1.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

2.  Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Authors:  Yagmur Muftuoglu; Christal D Sohl; Andrea C Mislak; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antiviral Res       Date:  2014-03-12       Impact factor: 5.970

3.  HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.

Authors:  Martina Kovarova; Uma Shanmugasundaram; Caroline E Baker; Rae Ann Spagnuolo; Chandrav De; Christopher C Nixon; Angela Wahl; J Victor Garcia
Journal:  J Antimicrob Chemother       Date:  2016-08-01       Impact factor: 5.790

4.  Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.

Authors:  Wei Zhang; Michael A Parniak; Stefan G Sarafianos; Marilyn R Cost; Lisa C Rohan
Journal:  Int J Pharm       Date:  2013-12-09       Impact factor: 5.875

Review 5.  Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Annu Rev Virol       Date:  2017-07-26       Impact factor: 10.431

6.  Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Authors:  Christal D Sohl; Rajesh Kasiviswanathan; Jiae Kim; Ugo Pradere; Raymond F Schinazi; William C Copeland; Hiroaki Mitsuya; Masanori Baba; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2012-04-18       Impact factor: 4.436

7.  Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Authors:  Karen A Kirby; Eleftherios Michailidis; Tracy L Fetterly; Musetta A Steinbach; Kamalendra Singh; Bruno Marchand; Maxwell D Leslie; Ariel N Hagedorn; Eiichi N Kodama; Victor E Marquez; Stephen H Hughes; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

8.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

Review 9.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.

Authors:  Martin Markowitz; Stefan G Sarafianos
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

10.  In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.

Authors:  Wei Zhang; Michael A Parniak; Stefan G Sarafianos; Philip E Empey; Lisa C Rohan
Journal:  Eur J Pharmacol       Date:  2014-03-29       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.